{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-007579","form_type":"8-K","ticker":"LYEL","cik":"0001806952","company_name":"Lyell Immunopharma, Inc.","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.607987+00:00","generated_at":"2026-06-05T09:18:51.629876+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lyell reports Q4 net loss $52.9M, full-year loss $234.6M; cash $562.7M supports pipeline into 2027","bullets":["Net loss $52.9M in Q4 2023 and $234.6M full year; non-GAAP net loss $43.9M Q4 and $177.4M FY.","Revenue $0.1M in FY2023 vs $84.7M in FY2022 due to termination of GSK collaboration in Dec 2022.","Cash $562.7M as of Dec 31, 2023; expected to fund operations into 2027.","Expect initial clinical data from LYL797 CAR T in H1 2024 and LYL845 TIL in H2 2024; LYL845 got FDA Orphan Drug Designation for melanoma.","Appointed Matt Lang as Chief Business Officer; IND submission for LYL119 expected H1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-007579","json":"https://secwatch.observer/filing/0001628280-24-007579.json","markdown":"https://secwatch.observer/filing/0001628280-24-007579.md","text":"https://secwatch.observer/filing/0001628280-24-007579.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806952/000162828024007579/0001628280-24-007579-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806952/000162828024007579/lyel-20240228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T09:18:51.629876+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b7ecf30e7aa5c2b8c33dbf884689b4d22b6265ce","claim":"Lyell Immunopharma, Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income $52.9 million.","evidence_excerpt":"Fourth Quarter and Full Year 2023 Financial Results Lyell reported a net loss of $52.9 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806952/000162828024007579/0001628280-24-007579-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Net income","value":"$52.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}